GSK may avoid China charges

 
City A.M. Reporter
CHINESE police investigating allegations of widespread corrupt practices at GlaxoSmithKline are likely to charge some of its Chinese executives but not the pharma giant itself, legal and industry sources say.

A charge against Glaxo itself would be a much more serious outcome for the company because it would imply higher-level corporate involvement and could result in major fines and even disruption to its operations in China, a key future source of growth.

Related articles